Delonix Bioworks Achieves Significant Regulatory Milestone
Delonix Bioworks, an innovative clinical-stage biotechnology company specializing in next-generation bacterial vaccines, recently announced a major milestone: its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance from China’s National Medical Products Administration (NMPA). Following the successful completion of Clinical Trial Notification (CTN) procedures and ethics committee approval in Australia, Delonix is gearing up to initiate Phase I clinical trials to evaluate DX-104's safety and immunogenicity in human subjects.
Understanding Invasive Meningococcal Disease
Invasive meningococcal disease (IMD) is a serious bacterial infection that primarily affects infants, adolescents, and young adults. Among the different serogroups of meningococci, Serogroup B stands out as a leading cause of IMD globally, responsible for nearly 50% of cases and its prevalence continuing to rise. Although vaccines like GSK's Bexsero and Pfizer's Trumenba have demonstrated considerable clinical and commercial success—Bexsero alone achieving approximately $1.58 billion in sales recently—there remain significant gaps concerning global access and strain coverage that need to be addressed.
Innovative Development of DX-104
DX-104 is developed through Delonix's groundbreaking OMV Plus platform, which utilizes precisely engineered outer membrane vesicles (OMVs) that possess intrinsic adjuvant properties, enhancing immunogenicity. In preclinical assessments, DX-104 has shown to induce strong serum bactericidal antibody (SBA) responses without reliance on external adjuvants, showcasing its potential effectiveness. The production process for DX-104 has reached commercial scale, ensuring high consistency between batches and establishing a robust global supply chain as the candidate moves closer to commercialization.
Leadership Perspective on Future Endeavors
"Receiving dual regulatory clearances in China and Australia is a transformative moment for Delonix Bioworks as we evolve into a clinical-stage entity," stated Qiubin Lin, CEO and Founder of Delonix Bioworks. "This achievement is a pivotal part of our global strategy aimed at deploying engineered bacterial vaccines that are not only highly immunogenic but also well-tolerated and scalable. We are dedicated to meeting the urgent medical needs that patients face around the world.”
About Delonix Bioworks
Delonix Bioworks stands at the forefront of clinical-stage biotechnology, focusing on the creation of advanced genetically engineered bacterial vaccines. With its proprietary OMV Plus platform, the company effectively produces high-yield, cost-efficient outer membrane vesicles designed to enhance antigen presentation and immunogenicity. Delonix is committed to advancing a diverse pipeline of first-in-class and best-in-class vaccines addressing critical health needs, including those targeting Meningococcal B, pertussis, gonorrhoeae, and K. pneumoniae.
Frequently Asked Questions
What is DX-104?
DX-104 is an engineered vaccine candidate for Group B meningococcal disease developed by Delonix Bioworks.
Why is there a need for vaccines like DX-104?
There is a significant public health challenge with Invasive Meningococcal Disease (IMD), particularly from Serogroup B, which has increased cases globally.
What are the next steps for Delonix Bioworks?
Delonix plans to commence Phase I clinical trials to assess the safety and immunogenicity of DX-104 in humans shortly.
How does the OMV Plus platform work?
The OMV Plus platform uses engineered outer membrane vesicles with intrinsic adjuvant properties that improve Immunogenicity without the need for external adjuvants.
Who leads Delonix Bioworks?
Delonix Bioworks is led by Qiubin Lin, CEO and Founder, who emphasizes the company's commitment to global health needs.
